The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

A nationwide shortage of BCG vaccines in the country leaves Kenyan newborns vulnerable to TB, a disease with a high ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study ...

Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBCCompleted approximately $100 million public offering, ...

Scientists have developed a breakthrough mechanism that makes the intravenous Bacillus Calmette-Guérin (BCG) tuberculosis ...

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

1Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland. *Corresponding Author: Laronna Colbert, Office of Clinical Evaluation, CBER, U.S. Food and ...

Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...